Is atherosclerosis exclusively a postprandial phenomenon?

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 3-4, 1997, Pages 288-293

  Mamo, John C L ^a   Yu, Kenneth C W ^a   Elsegood, Caryn L ^a   Smith, Darrin ^a   Vine, Donna ^a   Gennat, Hanni C ^a   Voevodin, Melanie ^a   Proctor, Spencer D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Atherosclerosis; Chylomicrons; Low density lipoproteins; Postprandial phenomenon

Indexed keywords

CHYLOMICRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; LIPID METABOLISM; POSTPRANDIAL STATE;

EID: 0030986081     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01822.x     Document Type: Conference Paper

References (48)

1. Brown M, Goldstein }L. Heart attacks: Gone with the century? Science 1996; 272: 629.
2. Martin MJ, Hulley SB, Browner VS et al. Serum cholesterol, blood presssure and mortality: Implications from a cohort of 361 662 men. Lancet 1986; 293: 306-7.
3. Kannell VB, Gordon T, Castelli VP. Role of lipids and lipoprotein fractions in assessing atherogenesis. The Framingham Study. Prog. Lipid Res. 1981; 20: 339-48.
4. Watts GF. Lipid lowering therapy and regression of atherosclerosis. Endocrinol. Metab. 1994; 1: 71-87.
5. Zilversmit DB. Atherogenesis: A postprandial phenomenon. Circulation 1979; 3: 473-85.
6. Hennessy LK, Osada J, Ordovas JM et al. Effects of dietary fats and cholesterol on liver lipid content and hepatic apolipoprotein A-I, B, and E and LDLreceptor mRNA levels in cebus monkeys. J. Lipid Res. 1992; 33: 351-60.
7. Redgrave TO. Formation and metabolism of chylomicrons. Int. Rev. Physiol. 1983; 28: 103-30.
8. Thompson GR. A handbook of hyperlipidaemia. London: Current Science; 1990.
9. Martins IJ, Sainsbury AJ, Mamo JCL, Redgrave TG. Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron like emulsions in insulin deficient rats. Diabetologia 1994; 37: 238-46.
10. Bitzen U, Winqvist M, Nilsson-Ehle P, Fex G. Retinyl palmitate is a reproducible marker for chylomicron elimination from blood. Scand. J. Clin. Lab. Invest. 1994; 54: 611-13.
11. Loirdighi N, Menard D, Levy E. Insulin decreases chylomicron production in human fetal small intestine. Biochim. Biopliys. Acta 1992; 1175: 100-6.
12. Kahn HA, Phillips RL. Association between reported diet and all cause mortality: Twenty-one year follow up on 27530 adult Seventh Day Adventists. Am. J. Epidemiol. 1984; 119: 775-87.
13. Mattson FH, Grundy SM. Comparison of effects of dietary saturated, monounsaturated and polyunsaturated fatty acids on plasma lipids, lipoproteins and apoproteins in humans. Am. J. Clin. Nutr. 1983; 37:355-60.
14. Fielding CJ. Lipoprotein receptors, plasma cholesterol metabolism and the regulation of cellular free cholesterol concentration. FASEB J. 1992; 6: 3162-8.
15. Lees RS, Wilson DE. The treatment of hyperlipidemia. N. Engl. J. Med. 1971; 284: 186-95.
16. Redgrave TG. A new approach to the physiology of lipid transport. News Physiol. Sei. 1988; 3: 10-3.
17. Soutar AK, Myant NB, Thompson GR. Simultaneous measurement of apolipoprotein B turnover in very low density and low density lipoproteins in familial hypercholesterolaemia. Atherosclerosis 1977; 28: 247-56.
18. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of postprandial triglycéride rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B48 and B100. Arterioscler. Tliromb. Vase. Biol. 1995; 15: 199-207.
19. Julius U, Fritsch H, Rehak E, Fucker K, Leonhardt W, Hanefeld M. Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein (la) in nomolipidemic postmenopausal women. Clin. Invest. 1994; 72: 502-7.
20. Smith D, Proctor SD, Mamo JCL. A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann. Clin. Biochem. 1997; 34 (in press).
21. Mamo JCL. Atherosclerosis as a postprandial disease. Endocrinol. Metab. 1995; 2: 229-44.
22. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
23. Kita T, Goldstein JL, Brown MS, Watanabe Y, Hornick CA, Havel RJ. Hepatic uptake of chylomicron remnants in WHHL rabbits: A mechanism genetically distinct from the low density lipoprotein receptor. Proc. NallAcad. Sei. USA 1982; 79: 3623-7.
24. Rubinsztein DC, Cohen JC, Berger M, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 1990; 86: 1306-12.
25. Hussain MM, Innerarity TL, Brecht WJ, Mahley RW. Chylomicron metabolism in normal cholesterol-fed and Watanabe heritable hyperlipidemic rabbits. J. Biol. Chem. 1995; 270: 8578-87.
26. Innerarity TL, Mahley R. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978; 17: 1440-7.
27. Bowler A, Redgrave TG, Mamo JCL. Chylomicron remnant clearance in homozygote and hétérozygote Watanabe heritable hyperlipidemic rabbits is defective. Lack of evidence for an independent chylomicronremnant receptor. Biochem. J. 1991; 276: 381-6.
28. Breslow JL, Zannis VI, Aangiacomo TR, Third JLHC, Tracy T, Glueck CJ. Study of familial type III hyperlipoproteinemia using as a genetic marker apo E phenotype E2/E2. J. LipidRes. 1982; 23: 1224-35.
29. Potts JL, Coppack, SW, Fisher RM, Humphreys SM, Gibbons GH, Frayn KN. Impaired postprandial clearance of triacylglycerol rich lipoproteins in adipose tissue in obese subjects. Am. J. Physiol. 1995; 268: E588-94.
30. Kaysen GA, Mehendru L, Pan XM, Staprans I. Both peripheral chylomicron catabolism and hepatic uptake of remnants are defective in nephrosis. Am. J. Physiol. 1992; 263: F335-41.
31. Zerbinatti CV, Oliveira HC, Wechesler S, Quintao EC. Independent regulation of chylomicron lipolysis and particle removal rates: Effects of insulin and thyroid hormones on the metabolisms of artificial chylomicrons. Metab. Clin. Exp. 1991; 40: 1122-7.
32. Wientraub M, Burstein A, Rassin T et al. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int. 1992; 42: 1247-52.
33. Gylling H, Miettinen TA. Postabsorptive retinyl palmitate removal is retarded in lecithin cholesterol acyltransferase deficiency. Etir. J. Clin. Invest. 1993; 23: 302-6.
34. Nordestgaard BG, Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atherosclerosis. Ear. J. Epidemiol. 1982; 8: 92-8.
35. Simionescu N, Simionescu M. Cellular interactions of lipoproteins with the vascular endothelium: Endocytosis and transcytosis. Targeted DiagruTlier. 1991; 5: 45-95.
36. Mamo JCL, Wheeler JR. Chylomicrons or their remnants penetrate rabbit thoracic aorta as efficiently as smaller macromolecules including low density lipoprotein, high density lipoprotein and albumin. Coron. Artery Dis. 1994; 5: 695-705.
37. Proctor SD, Mamo JCL. Arterial fatty lesions have increased uptake of chylomicron remnants but not low-density lipoproteins. Coron. Artery Dis. 1996; 7: 239-45.
38. Gown AM, Tsukada T, Ross R. Human atherosclerosis II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am. J. Palhol. 1986; 125: 191-200.
39. Koo C, Wernette-Hammond ME, Garcia Z et al. Uptake of cholesterol rich remnant lipoproteins by human monocyte-derived macrophages is mediated by low density lipoprotein receptors. J. Clin. Invest. 1988; 81 : 1332-40.
40. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Nail Acad. Sei. USA 1979; 76: 333-7.
41. Morel DW, DiCorletto PE, Chisholm GV. Endothelial and smooth muscle cells alter low density lipoproteins in vitro by free radical oxidation. Arterioscler. Tliromb. 1984; 4: 357-64.
42. Mamo JCL, Elsegood C, Umeda Y, Hirano T, Redgrave TG. Effect of probucol on plasma clearance and organ uptake of chylomicrons and very low density lipoproteins in normal and diabetic rats. Arterioscler. Tliromb. 1993; 13: 231-9.
43. Walldius G, Erikson U, Olsson AG et al. The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. 1994; 74: 875-83.
44. Nagano Y, Yokode M, Ishii K et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. Proc. NatlAcad. Sei. USA 1987; 84: 5928-31.
45. Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T. Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 1983; 48: 157-66.
46. Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley RW. Cholesteryl ester accumulation in macrophages resulting from receptormediated uptake and degradation of hypercholesterolemic canine betavery low density lipoproteins. J. Biol. Cliem. 1980; 255: 1839-45.
47. VanLenten BJ, Fogelman AM, Jackson RL, Shapiro S, Haberland ME, Edwards PA. Receptor mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte macrophages. J. Biol. Cheni. 1985; 260: 8783-8.
48. Mamo JCL, Elsegood CL, Gennat HC, Yu K. Degradation of chylomicron remnants by macrophages occurs via phagocytosis. Biochemistry 1996; 35: 10210-14.